ALK Gene Copy Number Gain and Immunohistochemical Expression Status Using Three Antibodies in Neuroblastoma

Abstract

Anaplastic lymphoma kinase (ALK) gene aberrations—such as mutations, amplifications, and copy number gains—represent a major genetic predisposition to neuroblastoma (NB). This study aimed to evaluate the correlation between ALK gene copy number status, ALK protein expression, and clinicopathological parameters. We retrospectively retrieved 30 cases of poorly differentiated NB and constructed tissue microarrays (TMAs). ALK copy number changes were assessed by fluorescence in situ hybridization (FISH) assays, and ALK immunohistochemistry (IHC) testing was performed using three different antibodies (ALK1, D5F3, and 5A4 clones). ALK amplification and copy number gain were observed in 10% (3/30) and 53.3% (16/30) of the cohort, respectively. There were positive correlations between ALK copy number and IHC-positive rate in ALK1 and 5A4 antibodies (P < 0.001 and P = 0.019, respectively). ALK1, D5F3, and 5A4 antibodies equally showed 100% sensitivity in detecting ALK amplification. However, the sensitivity for detecting copy number gain differed among the three antibodies, with 75% sensitivity in D5F3 and 0% sensitivity in ALK1. ALK-amplified NBs were correlated with synchronous MYCN amplification and chromosome 1p deletion. ALK IHC positivity was frequently observed in INSS stage IV and high-risk group patients. In conclusion, this study identified that an increase in the ALK copy number is a frequent genetic alteration in poorly differentiated NB. ALK-amplified NBs showed consistent ALK IHC positivity with all kinds of antibodies. In contrast, the detection performance of ALK copy number gain was antibody dependent, with the D5F3 antibody showing the best sensitivity.

Keywords

copy number gain fluorescence in situ hybridization immunohistochemistry neuroblastoma

Get full access to this article

View all access options for this article.

References

Chen

Takita

Choi

. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008; 455: 971–974.

Brodeur

Seeger

Schwab

Varmus

Bishop

. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984; 224: 1121–1124.

Attiyeh

London

Mosse

. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005; 353: 2243–2253.

Maris

Weiss

Guo

. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J Clin Oncol 2000; 18: 1888–1899.

Bown

Cotterill

Lastowska

. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999; 340: 1954–1961.

Pulford

Lamant

Morris

. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 1997; 89: 1394–1404.

Caren

Abel

Kogner

Martinsson

. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 2008; 416: 153–159.

Mosse

Laudenslager

Longo

. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455: 930–935.

De Brouwer

De Preter

Kumps

. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 2010; 16: 4353–4362.

10.

Subramaniam

Piqueras

Navarro

Noguera

. Aberrant copy numbers of ALK gene is a frequent genetic alteration in neuroblastomas. Hum Pathol 2009; 40: 1638–1642.

11.

Janoueix-Lerosey

Lequin

Brugieres

. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008; 455: 967–970.

12.

Mosse

Lim

Voss

. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol 2013; 14: 472–480.

13.

Wang

Zhou

Sun

. ALK amplification and protein expression predict inferior prognosis in neuroblastomas. Exp Mol Pathol 2013; 95: 124–130.

14.

Duijkers

Gaal

Meijerink

. High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome. Am J Pathol 2012; 180: 1223–1231.

15.

Passoni

Longo

Collini

. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res 2009; 69: 7338–7346.

16.

Schulte

Bachmann

Brockmeyer

. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. Clin Cancer Res 2011; 17: 5082–5092.

17.

Shimada

Ambros

Dehner

. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999; 86: 364–372.

18.

Joshi

Cantor

Altshuler

. Recommendations for modification of terminology of neuroblastic tumors and prognostic significance of Shimada classification. A clinicopathologic study of 213 cases from the Pediatric Oncology Group. Cancer 1992; 69: 2183–2196.

19.

Ambros

Benard

Boavida

. Quality assessment of genetic markers used for therapy stratification. J Clin Oncol 2003; 21: 2077–2084.

20.

Ambros

. Siop Europe Neuroblastoma Pathology, Biology Bone Marrow Group. Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol 2001; 37: 492–504.

21.

Cheung

Dyer

. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer 2013; 13: 397–411.

22.

Yan

Kuick

Lim

. Platform comparison for evaluation of ALK protein immunohistochemical expression, genomic copy number and hotspot mutation status in neuroblastomas. PLoS One 2014; 9: e106575.

23.

Carpenter

Mosse

. Targeting ALK in neuroblastoma—Preclinical and clinical advancements. Nat Rev Clin Oncol 2012; 9: 391–399.

24.

Mino-Kenudson

Chirieac

Law

. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010; 16: 1561–1571.

25.

Duijkers

Gaal

Meijerink

. Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels. Cell Oncol (Dordr) 2011; 34: 409–417.